Lyell Immunopharma

Lyell Immunopharma is a clinical-stage T-cell reprogramming company developing cell therapies for patients with solid tumors and hematologic malignancies. The company's technology platforms focus on addressing two key barriers in cell therapy: T-cell exhaustion and lack of durable stemness. Its lead product candidate, LYL797, is a ROR1-targeted CAR T-cell therapy enhanced with proprietary anti-exhaustion technology. In June 2024, Phase 1 trial data for LYL797 showed a 40% objective response rate and 60% clinical benefit rate at the 150 x 106 CAR T cell dose level in triple-negative breast cancer patients. The company's second pipeline candidate, LYL119, is a next-generation ROR1-targeted CAR T-cell therapy incorporating enhanced anti-exhaustion technology. In October 2024, Lyell acquired ImmPACT Bio, adding IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for B-cell lymphoma, to its pipeline. Following this acquisition, Lyell discontinued development of LYL797, LYL845, and earlier-stage TIL programs to prioritize IMPT-314 and LYL119. The company manufactures its cell therapies at its LyFE Manufacturing Center.

Key customers and partnerships

In 2019, Lyell entered into a collaboration agreement with GSK to research and develop T-cell therapies that apply Lyell's platform technologies to TCRs or chimeric antigen receptor therapies. The collaboration includes LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing NY-ESO-1. In January 2022, the FDA cleared an IND application for LYL132, which the company is developing in partnership with GSK for the treatment of synovial sarcoma and myxoid/round cell liposarcoma.